tirzepatide monograph FDA Says Compounded Must Exit the Market Microdosing tirzepatide is an emerging

10.1016/j.bbrc.2005.01.139 339

DNA methylation-based estimator of telomere length

IN PRACTICE: GLP-1 RAs offer promise for patients with HS and obesity and potentially for patients without obesity through immunological effects, the study authors wrote

The evaluated GLP-1RAs were semaglutide (IC 025 = 2.13), liraglutide (IC 025 = 1.18), dulaglutide (IC 025 = 3.76), exenatide (IC 025 = 3.52), and albiglutide (IC 025 = 3.91), none of which exhibited a signal of disproportionate reporting

While the most common side effects of GLP-1 receptor agonists are gastrointestinal issues like nausea and vomiting, the less common but more severe effects include gastroparesis and pancreatitis

While CPAP (Continuous Positive Airway Pressure) remains the gold standard for treating moderate to severe sleep apnea, weight loss through Tirzepatide can significantly reduce the need for CPAP therapy